U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
PR Newswire —
INGELHEIM, Germany and RIDGEFIELD, Conn., Dec. 22, 2025 Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 Affecting up to 100,000 people in the U.S. and up to 5.6 million worldwide, PPF is linked to an...